PRTK Stock Recent News

BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announces that new data from NUZYRA® (omadacycline) scientific and investigator-initiated research programs will be presented at IDWeek 2023.

BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Tuesday, May 9 at 4:30 p.m. EDT to report financial results for first quarter 2023. The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com. Domestic investors wishing to participate in the call will dial: 800-920-3371 and international investors will dial: +1-212-231-2909. The conference ID is 22026760. Investors can also access the call at: https://viavid.webcasts.com/starthere.jsp?ei=1611304&tp_key=5fe62a51b9 About Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use. The company's lead

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK ) Q4 2022 Earnings Conference Call March 16, 2023 8:30 AM ET Company Participants Sarah Higgins - VP, Finance, and Principal Accounting Officer Evan Loh - CEO Adam Woodrow - President and Chief Commercial Officer Randall Brenner - Chief Development and Regulatory Officer Conference Call Participants Suji Jeong - Jefferies Robert Hazlett - BTIG Ed Arce - H.C. Wainwright Operator Greetings, and welcome to the Paratek Pharmaceuticals Fourth Quarter and Full Year 2022 Earnings Call.

BOSTON, March 08, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Thursday, March 16, 2023 at 8:30 a.m. EST to provide a corporate update and report its financial results for fourth quarter and full year 2022.

BOSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announces that Evan Loh, M.D., chief executive officer, will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Wednesday, Nov. 30 at 9:15 a.m. ET.

Paratek (PRTK) delivered earnings and revenue surprises of -40.74% and 13.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, announces that Evan Loh, M.D., chief executive officer, will present at the Credit Suisse 31st Annual Healthcare Conference held Nov. 7-10. Dr. Loh's presentation will be available on-demand beginning Nov. 8 under “Presentations & Events" in the Investors section of the company's website. https://www.paratekpharma.com/investor-relations About Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use. The company's lead commercial product, NUZY

BOSTON, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Thursday, Nov. 3 at 4:30 p.m. ET to report its financial results for the third quarter of 2022. The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com. Domestic investors wishing to participate in the call should dial 800-458-4121 and international investors should dial +1-646-828-8193. The conference ID is 7165992. Investors can also access the event at: https://viavid.webcasts.com/starthere.jsp?ei=1577240&tp_key=22e88571f9. About Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use. Th

BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that Paratek President and Chief Commercial Officer Adam Woodrow will participate in a virtual fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference. The hybrid conference will be held from Sept. 12-14, with in-person participation held at the Lotte New York Palace Hotel. Mr. Woodrow's event will be available to view on-demand at: https://journey.ct.events/view/50615e23-aa8f-4cbd-b346-07b27991853f and under "Presentations & Events" in the Investors section of the company's website at https://www.paratekpharma.com/investor-relations beginning Sept. 12 at 7 a.m. ET and for the next 90 days. Members of Paratek's senior management team w

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Sarah Higgins - VP, Controller and Interim Principal Financial & Accounting Officer Evan Loh - CEO & Director Adam Woodrow - President & Chief Commercial Officer Randall Brenner - Chief Development & Regulatory Officer Conference Call Participants Suji Jeong - Jefferies Antonio Arce - H.C. Wainwright & Co. Robert Hazlett - BTIG Operator Good day, and welcome to Paratek Pharmaceuticals Second Quarter 2020 Earnings Conference Call.